After matching, patient and tumor characteristics were well balanced (Table On Fine‐Gray regression in the matched cohorts, the adjusted hazard ratio of CSM for cetuximab was 1.65 (95% confidence interval [CI], 1.30‐2.09; Finally, we analyzed the comparative acute toxicities associated with receipt of cisplatin or cetuximab in the matched cohorts, as determined by claims corresponding to a diagnosis of dermatitis, mucositis, or dysphagia within 3 months from the initiation of RT.

Patients who received fewer cycles were labeled as having … Unable to load your collection due to an error Search for other works by this author on: were supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.Oxford University Press is a department of the University of Oxford.

Radiother Oncol 2006;79:34-38. The radiation course was disrupted in two of the patients by adverse events. In a randomized trial, weekly cisplatin plus radiotherapy has been shown to be not only less toxic than dosing once every three weeks but also achieves better outcomes. Another limitation is that SEER lacks data on RT details (such as fields, dose, or fractionation) and patterns of failure (such as local vs distant). The number of positive nodes, longer time between surgery and onset of radiotherapy, extracapsular extension and …

Compared with the matched cisplatin cohort, the matched cetuximab cohort had a significantly lower relative risk (RR) of dysphagia (RR, 0.83; 95% CI, 0.74‐0.94; Multiple randomized trials have demonstrated that concurrent cisplatin with RT is superior to RT alone.Although the patients who received cetuximab tended to be older and frailer than those who received cisplatin, we addressed this potential source of confounding using 3 different and complementary methodologies.

By continuing to browse this site, you agree to its use of cookies as described in our I have read and accept the Wiley Online Library Terms and Conditions of UseCetuximab: its unique place in head and neck cancer treatmentRecurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)‐radiotherapy [serial online]Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced‐stage oropharynx carcinomaAn intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancerPostoperative concurrent radiotherapy and chemotherapy for high‐risk squamous‐cell carcinoma of the head and neckPostoperative Irradiation with or without concomitant chemotherapy for locally advanced head and neck cancerMACH‐NC collaborative group.

Cancer Care Evaluation Scale (CCES): measuring the quality of the structure and process of cancer care from the perspective of patients with cancer If you do not receive an email within 10 minutes, your email address may not be registered,

All of the patients received external RT (40 Gy/20 fractions/4 weeks), in the form of 4 or 6 MV photons produced by a linear accelerator, to the primary sites and regional lymphatic area.

Third, we measured comorbidity using the Charlson index and then applied propensity score matching to balance the cisplatin and cetuximab groups, followed by multivariable regression in the matched cohorts. 2019 Oct 7;11(10):1499. doi: 10.3390/cancers11101499.Hägerström E, Lindberg L, Bentzen J, Brødbæk K, Zerahn B, Kristensen B.Clin Med Insights Oncol. A randomized controlled trial conducted in India compared cisplatin administered weekly vs. every 3 weeks among patients with head and neck cancer. Search for other works by this author on: In four of these patients, no viable cancer cells were observed in the surgical specimens.